VE-822 ATR Inhibitor: Selective DNA Damage Response Blockade in Pancreatic Cancer Research

Executive Summary: VE-822 (APExBIO B1383) is a potent, selective ATR kinase inhibitor with an IC50 of 0.019 μM, targeting DNA damage response (DDR) signaling in cancer cells. It demonstrates increased potency over its analog VE-821 and sensitizes pancreatic ductal adenocarcinoma (PDAC) cells with p53 and K-Ras mutations to chemoradiotherapy, while minimizing toxicity in normal cells (APExBIO). VE-822 blocks ATR-mediated checkpoint activation and homologous recombination repair, resulting in persistent DNA damage in tumor cells. In vivo, it prolongs tumor growth delay in combination with gemcitabine and radiation without elevating adverse effects on healthy tissue (Sequiera et al., 2022). The compound is supplied as a 463.55 Da small molecule, with optimal solubility in DMSO (≥50 mg/mL), and is intended exclusively for research use.

Biological Rationale

ATR (ATM-Rad3-related) kinase is a serine/threonine protein kinase essential for the cellular response to DNA replication stress and double-strand DNA breaks. ATR is activated by regions of single-stranded DNA (ssDNA) bound by replication protein A (RPA), a hallmark of replication stress induced by cytotoxic agents or oncogenic signaling (Sequiera et al., 2022). In cancer, particularly PDAC with p53 and K-Ras mutations, reliance on ATR-mediated checkpoint and repair pathways is heightened, creating a therapeutic window for selective DDR inhibition. Pharmacological blockade of ATR sensitizes tumor cells to DNA-damaging therapies and can overcome intrinsic resistance mechanisms. Normal cells, with intact G1/S checkpoints and lower replication stress, are less dependent on ATR, reducing off-target toxicity risks.

Mechanism of Action of VE-822 ATR inhibitor

VE-822 is a small molecule inhibitor that binds the ATP-binding site of ATR, inhibiting its kinase activity with high selectivity (IC50 = 0.019 μM). This blockade prevents phosphorylation of key substrates such as Chk1, abrogating S and G2/M cell cycle checkpoints. The result is a rapid progression of damaged cells into mitosis without adequate repair, leading to cell death, particularly in DDR-deficient or checkpoint-compromised cancer cells (APExBIO). VE-822 also suppresses homologous recombination repair (HRR), further enhancing DNA damage accumulation after irradiation or genotoxic chemotherapy. The specificity for ATR over ATM and DNA-PK is critical for minimizing off-target effects.

Evidence & Benchmarks

• VE-822 inhibits ATR kinase activity with an IC50 of 0.019 μM in biochemical assays (APExBIO).
• In PDAC models, VE-822 enhances radiosensitivity and chemosensitivity (notably to gemcitabine) by increasing persistent γH2AX foci, indicating unrepaired DNA damage (Sequiera et al., 2022).
• In vivo, the combination of VE-822 with radiation and gemcitabine significantly prolongs tumor growth delay in pancreatic xenografts without increasing normal tissue toxicity (Sequiera et al., 2022).
• VE-822 displays markedly increased potency compared to its analog VE-821 due to optimized molecular structure for ATR binding (APExBIO).
• VE-822 is insoluble in water and ethanol but highly soluble in DMSO at ≥50 mg/mL when warmed to 37°C and sonicated (APExBIO).

For an in-depth look at workflow optimization, see "VE-822 ATR Inhibitor: Sensitizing Pancreatic Cancer via DDR Disruption"; this article extends those findings by detailing product-specific handling and cross-validating with recent iPSC-based efficacy screens.

Comparatively, "VE-822 ATR Inhibitor: Precision Tools for DNA Damage Response" focuses on personalized therapy; this dossier updates with new quantitative solubility and in vivo benchmarks.

Applications, Limits & Misconceptions

VE-822 is primarily used for preclinical research on ATR signaling, DNA damage response inhibition, and chemosensitization of resistant tumors, especially PDAC with p53/K-Ras mutations. It is not approved for clinical use in humans. Its activity profile is best characterized in cancer cell lines and xenograft models. The product is intended for research use only and should not be used for diagnostic or therapeutic purposes in patients.

Common Pitfalls or Misconceptions

• VE-822 does not inhibit ATM or DNA-PK at equivalent concentrations; selectivity must be confirmed in each system.
• It is not water or ethanol soluble; improper solvent selection leads to precipitation or loss of activity.
• Stock solutions degrade if repeatedly thawed; always store aliquots at -20°C and use promptly.
• VE-822 is not a clinical drug; in vivo findings in animal models may not translate directly to clinical efficacy.
• Its efficacy depends on ATR pathway dependency in target cells; tumors without replication stress or DDR defects may not respond.

Workflow Integration & Parameters

VE-822 is supplied as a solid, with recommended dissolution in DMSO at ≥50 mg/mL. Warming to 37°C and ultrasonic shaking are advised for optimal solubility. Prepare fresh aliquots to minimize freeze-thaw cycles and degradation. For in vitro studies, final DMSO concentrations should not exceed 0.1–0.5% to avoid solvent toxicity. For in vivo use, co-administration protocols should be optimized based on pharmacokinetics and animal model guidelines. VE-822 is shipped on blue ice; confirm product integrity upon receipt. For translational workflows, the product enables combination studies with radiation and DNA-damaging agents such as gemcitabine. For advanced guidance, see "VE-822 ATR Inhibitor: Precision DNA Damage Response Modulator"; this dossier adds updated solubility and storage parameters.

Conclusion & Outlook

VE-822 (APExBIO B1383) is a validated, high-potency ATR inhibitor for research applications in DNA damage response, with robust preclinical evidence supporting its role in the selective sensitization of pancreatic cancer models to chemoradiotherapy. Its favorable selectivity and solubility profile, combined with workflow compatibility, position it as a preferred tool for translational oncology. Ongoing advances in iPSC-based screening and precision oncology may further extend the utility of VE-822 in preclinical drug development (Sequiera et al., 2022).